{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:09:10Z","timestamp":1791821350140,"version":"4.3.4"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007514","name":"Universit\u00e0 di Pisa","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007514","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Light chain deposition disease (LCDD) is a rare hematologic disorder characterized by the deposition of non-amyloid monoclonal light chains in several organs. Together with renal impairment is being the primary morbidity associated with this disease. Due to its rarity, randomized clinical trials lack to explore treatment strategies and there are no approved or universally accepted standard of care treatment options. We aimed to provide a systematic summary of histological and clinical aspects of LCDD and treatment options of available literature therapies strategies. Currently, drugs used to treat multiple myeloma are recommended when LCDD patients also presented multiple myeloma. Anyway, in patients with LCDD that is not associated to multiple myeloma, haematopoietic stem cell transplantation (ASCT) and chemotherapy with thalidomide, dexamethasone, bortezomib are also recommended. In eligible patients, bortezomib-based chemotherapy followed by ASCT appears to be an effective treatment option with durable hematologic remission and organ responses. Although it appears that the patients undergoing ASCT seem to achieve deeper and durable hematologic remissions and organ responses, no statistically significant superiority can be demonstrated over non-transplant or standard chemotherapy-based approaches. As retrieved by our review, bortezomib-based therapy appears to be favorable strategy as long as no dose modification is required for renal impairment, and early hematologic responses as a recovery of renal function. Encouraging data were also demonstrated by treatment lenalidomide or melpalan based. Moreover, new myeloma treatment strategies, as monoclonal antibody Daratumumab, seem to be effective in LCDD. Instead, renal allograft is not recommended, due to high incidence of relapse.<\/jats:p>","DOI":"10.1007\/s00277-024-05911-9","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T01:02:10Z","timestamp":1724806930000},"page":"2083-2093","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Light chain deposition disease: pathogenesis, clinical characteristics and treatment strategies"],"prefix":"10.1007","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3156-3857","authenticated-orcid":false,"given":"Raffaella","family":"Cassano Cassano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo Giovanni","family":"Bonadio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Livia","family":"Del Giudice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Giannese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Galimberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5240-5611","authenticated-orcid":false,"given":"Gabriele","family":"Buda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,28]]},"reference":[{"issue":"6","key":"5911_CR1","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1053\/j.ajkd.2003.08.040","volume":"42","author":"C Pozzi","year":"2003","unstructured":"Pozzi C, D\u2019Amico M, Fogazzi GB, Curioni S, Ferrario F, Pasquali S, Quattrocchio G, Rollino C, Segagni S, Locatelli F (2003) Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. Am J Kidney Dis 42(6):1154\u20131163. https:\/\/doi.org\/10.1053\/j.ajkd.2003.08.040","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"5911_CR2","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I et al (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 36(7):1270\u20131748. https:\/\/doi.org\/10.1038\/s41375-022-01620-2","journal-title":"Leukemia"},{"issue":"7","key":"5911_CR3","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.3390\/cancers12071741","volume":"12","author":"P Men\u00e8","year":"2020","unstructured":"Men\u00e8 P, De Alexandris L, Moioli A, Raffa S, Stoppacciaro A (2020) Monoclonal Gammopathies of Renal Significance: Renal Biopsy and Beyond. Cancers (Basel) 12(7):1741. https:\/\/doi.org\/10.3390\/cancers12071741","journal-title":"Cancers (Basel)"},{"issue":"6","key":"5911_CR4","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.2215\/CJN.01730506","volume":"1","author":"P Ronco","year":"2006","unstructured":"Ronco P, Plaisier E, Mougenot B, Aucouturier P (2006) Immunoglobulin light (heavy)-chain deposition disease: from molecular medicine to pathophysiology-driven therapy. Clin J Am Soc Nephrol 1(6):1342\u20131350. https:\/\/doi.org\/10.2215\/CJN.01730506","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"5911_CR5","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1272\/jnms.JNMS.2019_86-1","volume":"86","author":"G Kanzaki","year":"2019","unstructured":"Kanzaki G, Okabayashi Y, Nagahama K, Ohashi R, Tsuboi N, Yokoo T, Shimizu A (2019) Monoclonal Immunoglobulin Deposition Disease and Related Diseases. J Nippon Med Sch 86(1):2\u20139. https:\/\/doi.org\/10.1272\/jnms.JNMS.2019_86-1","journal-title":"J Nippon Med Sch"},{"issue":"1","key":"5911_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41581-018-0077-4","volume":"15","author":"N Leung","year":"2019","unstructured":"Leung N, Bridoux F, Batuman V, Chaidos A, Cockwell P, D\u2019Agati VD, Dispenzieri A, Fervenza FC, Fermand JP, Gibbs S, Gillmore JD, Herrera GA, Jaccard A, Jevremovic D, Kastritis E, Kukreti V, Kyle RA, Lachmann HJ, Larsen CP, Ludwig H, Markowitz GS, Merlini G, Mollee P, Picken MM, Rajkumar VS, Royal V, Sanders PW, Sethi S, Venner CP, Voorhees PM, Wechalekar AD, Weiss BM, Nasr SH (2019) The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nat Rev Nephrol 15(1):45\u201359. https:\/\/doi.org\/10.1038\/s41581-018-0077-4","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"5911_CR7","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1186\/s12967-019-02147-4","volume":"17","author":"Q Wang","year":"2019","unstructured":"Wang Q, Jiang F, Xu G (2019) The pathogenesis of renal injury and treatment in light chain deposition disease. J Transl Med 17(1):387. https:\/\/doi.org\/10.1186\/s12967-019-02147-4","journal-title":"J Transl Med"},{"issue":"20","key":"5911_CR8","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1056\/NEJMra1810907","volume":"384","author":"N Leung","year":"2021","unstructured":"Leung N, Bridoux F, Nasr SH (2021) Monoclonal Gammopathy of Renal Significance. N Engl J Med 384(20):1931\u20131941. https:\/\/doi.org\/10.1056\/NEJMra1810907","journal-title":"N Engl J Med"},{"issue":"4","key":"5911_CR9","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1053\/snep.2002.33673","volume":"22","author":"C Pozzi","year":"2002","unstructured":"Pozzi C, Locatelli F (2002) Kidney and liver involvement in monoclonal light chain disorders. Semin Nephrol 22(4):319\u2013330","journal-title":"Semin Nephrol"},{"issue":"7","key":"5911_CR10","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1681\/ASN.V1271558","volume":"12","author":"PM Ronco","year":"2001","unstructured":"Ronco PM, Alyanakian MA, Mougenot B, Aucouturier P (2001) Light chain deposition disease: a model of glomerulosclerosis defined at the molecular level. J Am Soc Nephrol 12(7):1558\u20131565. https:\/\/doi.org\/10.1681\/ASN.V1271558","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"5911_CR11","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1681\/ASN.V1271482","volume":"12","author":"J Lin","year":"2001","unstructured":"Lin J, Markowitz GS, Valeri AM, Kambham N, Sherman WH, Appel GB, D\u2019Agati VD (2001) Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol 12(7):1482\u20131492. https:\/\/doi.org\/10.1681\/ASN.V1271482","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"5911_CR12","doi-asserted-by":"publisher","first-page":"875","DOI":"10.5858\/2004-128-875-RPSIAA","volume":"128","author":"GA Herrera","year":"2004","unstructured":"Herrera GA, Joseph L, Gu X, Hough A, Barlogie B (2004) Renal pathologic spectrum in an autopsy series of patients with plasma cell dyscrasia. Arch Pathol Lab Med 128(8):875\u2013879. https:\/\/doi.org\/10.5858\/2004-128-875-RPSIAA","journal-title":"Arch Pathol Lab Med"},{"key":"5911_CR13","doi-asserted-by":"publisher","first-page":"107368","DOI":"10.1016\/j.carpath.2021.107368","volume":"55","author":"M Hudak","year":"2021","unstructured":"Hudak M, Sardana R, Parwani AV, Mathewson RC, Gibson CG, Cohen PA, Lazarus JJ, Bruce JT, Son JH, Tynski Z (2021) Light chain deposition disease presenting as an atrial mass: a case report and review of literature. Cardiovasc Pathol 55:107368. https:\/\/doi.org\/10.1016\/j.carpath.2021.107368","journal-title":"Cardiovasc Pathol"},{"issue":"1","key":"5911_CR14","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/1752-1947-1-187","volume":"29","author":"F Fabbian","year":"2007","unstructured":"Fabbian F, Stabellini N, Sartori S, Tombesi P, Aleotti A, Bergami M, Uggeri S, Galdi A, Molino C, Catizone L (2007) Light chain deposition disease presenting as paroxysmal atrial fibrillation: a case report. J Med Case Rep 29(1):187. https:\/\/doi.org\/10.1186\/1752-1947-1-187","journal-title":"J Med Case Rep"},{"issue":"6","key":"5911_CR15","doi-asserted-by":"publisher","first-page":"821","DOI":"10.2143\/AC.64.6.2044752","volume":"64","author":"P Koopman","year":"2009","unstructured":"Koopman P, Van Dorpe J, Maes B, Dujardin K (2009) Light chain deposition disease as a rare cause of restrictive cardiomyopathy. Acta Cardiol 64(6):821\u2013824. https:\/\/doi.org\/10.2143\/AC.64.6.2044752","journal-title":"Acta Cardiol"},{"issue":"6","key":"5911_CR16","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/S1470-2045(04)01495-0","volume":"5","author":"P Went","year":"2004","unstructured":"Went P, Ascani S, Str\u00f8m E, Brorson SH, Musso M, Zinzani PL, Falini B, Dirnhofer S, Pileri S (2004) Nodal marginal-zone lymphoma associated with monoclonal light-chain and heavy-chain deposition disease. Lancet Oncol 5(6):381\u2013383. https:\/\/doi.org\/10.1016\/S1470-2045(04)01495-0","journal-title":"Lancet Oncol"},{"issue":"5","key":"5911_CR17","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1183\/09031936.00134406","volume":"29","author":"M Colombat","year":"2007","unstructured":"Colombat M, Gounant V, Mal H, Callard P, Milleron B (2007) Light chain deposition disease involving the airways: diagnosis by fibreoptic bronchoscopy. Eur Respir J 29(5):1057\u20131060. https:\/\/doi.org\/10.1183\/09031936.00134406","journal-title":"Eur Respir J"},{"issue":"5","key":"5911_CR18","doi-asserted-by":"publisher","first-page":"E145","DOI":"10.1148\/rg.220123","volume":"42","author":"DE Sweet","year":"2022","unstructured":"Sweet DE, Wheeler CA, Kearns C, Marquis KM (2022) Pulmonary Light-Chain Deposition Disease. Radiographics 42(5):E145\u2013E146. https:\/\/doi.org\/10.1148\/rg.220123","journal-title":"Radiographics"},{"issue":"8","key":"5911_CR19","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1373\/clinchem.2009.126664","volume":"55","author":"JA Katzmann","year":"2009","unstructured":"Katzmann JA, Kyle RA, Benson J, Larson DR, Snyder MR, Lust JA, Rajkumar SV, Dispenzieri A (2009) Screening panels for detection of monoclonal gammopathies. Clin Chem 55(8):1517\u201322. https:\/\/doi.org\/10.1373\/clinchem.2009.126664","journal-title":"Clin Chem"},{"issue":"1","key":"5911_CR20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.5414\/cnp71009","volume":"71","author":"R Masai","year":"2009","unstructured":"Masai R, Wakui H, Togashi M, Maki N, Ohtani H, Komatsuda A, Sawada K (2009) Clinicopathological features and prognosis in immunoglobulin light and heavy chain deposition disease. Clin Nephrol 71(1):9\u201320. https:\/\/doi.org\/10.5414\/cnp71009","journal-title":"Clin Nephrol"},{"issue":"9","key":"5911_CR21","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/clinchem\/48.9.1437","volume":"48","author":"JA Katzmann","year":"2002","unstructured":"Katzmann JA, Clark RJ, Abraham RS, Bryant S, Lymp JF, Bradwell AR, Kyle RA (2002) Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 48(9):1437\u20131444","journal-title":"Clin Chem"},{"key":"5911_CR22","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1159\/000314778","volume":"169","author":"P Ronco","year":"2011","unstructured":"Ronco P, Plaisier E, Aucouturier P (2011) Monoclonal immunoglobulin light and heavy chain deposition diseases: molecular models of common renal diseases. Contrib Nephrol 169:221\u2013231. https:\/\/doi.org\/10.1159\/000314778","journal-title":"Contrib Nephrol"},{"issue":"26","key":"5911_CR23","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1182\/blood-2015-07-658872","volume":"126","author":"RH Sayed","year":"2015","unstructured":"Sayed RH, Wechalekar AD, Gilbertson JA, Bass P, Mahmood S, Sachchithanantham S, Fontana M, Patel K, Whelan CJ, Lachmann HJ, Hawkins PN, Gillmore JD (2015) Natural history and outcome of light chain deposition disease. Blood 126(26):2805\u201310. https:\/\/doi.org\/10.1182\/blood-2015-07-658872","journal-title":"Blood"},{"issue":"8","key":"5911_CR24","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/ajh.24756","volume":"92","author":"M Mohan","year":"2017","unstructured":"Mohan M, Buros A, Mathur P, Gokden N, Singh M, Susanibar S, Jo Kamimoto J, Hoque S, Radhakrishnan M, Matin A, Davis C, Grazziutti M, Thanendrarajan S, van Rhee F, Zangari M, Davies F, Morgan G, Epstein J, Barlogie B, Schinke C (2017) Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease. Am J Hematol 92(8):739\u2013745. https:\/\/doi.org\/10.1002\/ajh.24756","journal-title":"Am J Hematol"},{"issue":"6","key":"5911_CR25","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1093\/ndt\/gfm918","volume":"23","author":"EC Lorenz","year":"2008","unstructured":"Lorenz EC, Gertz MA, Fervenza FC, Dispenzieri A, Lacy MQ, Hayman SR, Gastineau DA, Leung N (2008) Long-term outcome of autologous stem cell transplantation in light chain deposition disease. Nephrol Dial Transplant 23(6):2052\u20132057. https:\/\/doi.org\/10.1093\/ndt\/gfm918","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"5911_CR26","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/bmt.2011.87","volume":"47","author":"D Telio","year":"2012","unstructured":"Telio D, Shepherd J, Forrest D, Zypchen L, Barnett M, Nevill T, Song KW (2012) High-dose melphalan followed by auto-SCT has favorable safety and efficacy in selected patients with light chain deposition disease and light and heavy chain deposition disease. Bone Marrow Transplant 47(3):453\u2013455. https:\/\/doi.org\/10.1038\/bmt.2011.87","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"5911_CR27","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1093\/ndt\/gfaa361","volume":"37","author":"DW Chitty","year":"2022","unstructured":"Chitty DW, Hartley-Brown MA, Abate M, Thakur R, Wanchoo R, Jhaveri KD, Nair V (2022) Kidney transplantation in patients with multiple myeloma: narrative analysis and review of the last two decades. Nephrol Dial Transplant 37(9):1616\u20131626. https:\/\/doi.org\/10.1093\/ndt\/gfaa361","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"5911_CR28","doi-asserted-by":"publisher","first-page":"123","DOI":"10.14740\/jh1038","volume":"11","author":"A Masood","year":"2022","unstructured":"Masood A, Ehsan H, Iqbal Q, Salman A, Hashmi H (2022) Treatment of Light Chain Deposition Disease: A Systematic Review. J Hematol 11(4):123\u2013130. https:\/\/doi.org\/10.14740\/jh1038","journal-title":"J Hematol"},{"issue":"5","key":"5911_CR29","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/sj.bmt.1705447","volume":"38","author":"K Weichman","year":"2006","unstructured":"Weichman K, Dember LM, Prokaeva T, Wright DG, Quillen K, Rosenzweig M, Skinner M, Seldin DC, Sanchorawala V (2006) Clinical and molecular characteristics of patients with non-amyloid light chain deposition disorders, and outcome following treatment with high-dose melphalan and autologous stem cell transplantation. Bone Marrow Transplant 38(5):339\u2013343. https:\/\/doi.org\/10.1038\/sj.bmt.1705447","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"5911_CR30","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1002\/ajh.23235","volume":"87","author":"VH Jimenez-Zepeda","year":"2012","unstructured":"Jimenez-Zepeda VH, Trudel S, Winter A, Reece DE, Chen C, Kukreti V (2012) Autologous stem cell transplant for light chain deposition disease: incorporating bortezomib to the induction therapy. Am J Hematol 87(8):822\u2013823. https:\/\/doi.org\/10.1002\/ajh.23235","journal-title":"Am J Hematol"},{"issue":"21","key":"5911_CR31","doi-asserted-by":"publisher","first-page":"4600","DOI":"10.1182\/blood.V116.21.4600.4600","volume":"116","author":"VFN Jimenez Zepeda","year":"2010","unstructured":"Jimenez Zepeda VFN, Winter A, Reece D, Trudel S, Chen C, Rabea A, Kukreti V (2010) Light Chain Deposition Disease: impact of stem cell transplant on Hematological Response achievement. Blood 116(21):4600","journal-title":"Blood"},{"issue":"2","key":"5911_CR32","doi-asserted-by":"publisher","first-page":"300","DOI":"10.3324\/haematol.13548","volume":"94","author":"E Kastritis","year":"2009","unstructured":"Kastritis E, Migkou M, Gavriatopoulou M, Zirogiannis P, Hadjikonstantinou V, Dimopoulos MA (2009) Treatment of light chain deposition disease with bortezomib and dexamethasone. Haematologica 94(2):300\u20132. https:\/\/doi.org\/10.3324\/haematol.13548","journal-title":"Haematologica"},{"issue":"21","key":"5911_CR33","doi-asserted-by":"publisher","first-page":"5027","DOI":"10.1182\/blood.V120.21.5027.5027","volume":"120","author":"F Lessi","year":"2012","unstructured":"Lessi F, Castelli M, Trentin L, Altinier S, Piazza F, Adami F (2012) Bortezomib-Dexamethasone As Induction Therapy for Light Chain Deposition Disease (LCDD): A Single Center Experience. Blood. 120(21):5027","journal-title":"Blood."},{"issue":"2","key":"5911_CR34","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s12032-011-9938-4","volume":"29","author":"H Gharwan","year":"2012","unstructured":"Gharwan H, Truica CI (2012) Bortezomib-based chemotherapy for light chain deposition disease presenting as acute renal failure. Med Oncol 29(2):1197\u20131201. https:\/\/doi.org\/10.1007\/s12032-011-9938-4","journal-title":"Med Oncol"},{"issue":"2","key":"5911_CR35","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3109\/10428194.2011.622423","volume":"53","author":"MA Gertz","year":"2012","unstructured":"Gertz MA (2012) Managing light chain deposition disease. Leuk Lymphoma 53(2):183\u2013184. https:\/\/doi.org\/10.3109\/10428194.2011.622423","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"5911_CR36","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/j.1600-0609.2012.01821.x","volume":"89","author":"N Tovar","year":"2012","unstructured":"Tovar N, Cibeira MT, Rosi\u00f1ol L, Sol\u00e9 M, de Larrea CF, Escoda L, Rovira M, Blad\u00e9 J (2012) Bortezomib\/dexamethasone followed by autologous stem cell transplantation as front line treatment for light-chain deposition disease. Eur J Haematol 89(4):340\u2013344. https:\/\/doi.org\/10.1111\/j.1600-0609.2012.01821.x","journal-title":"Eur J Haematol"},{"issue":"3","key":"5911_CR37","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1096\/fj.05-4870fje","volume":"20","author":"S Fineschi","year":"2006","unstructured":"Fineschi S, Reith W, Guerne PA, Dayer JM, Chizzolini C (2006) Proteasome blockade exerts an antifibrotic activity by coordinately down-regulating type I collagen and tissue inhibitor of metalloproteinase-1 and up-regulating metalloproteinase-1 production in human dermal fibroblasts. FASEB J 20(3):562\u2013564. https:\/\/doi.org\/10.1096\/fj.05-4870fje","journal-title":"FASEB J"},{"key":"5911_CR38","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1159\/000096764","volume":"153","author":"J Keeling","year":"2007","unstructured":"Keeling J, Herrera GA (2007) The mesangium as a target for glomerulopathic light and heavy chains: pathogenic considerations in light and heavy chain-mediated glomerular damage. Contrib Nephrol 153:116\u2013134. https:\/\/doi.org\/10.1159\/000096764","journal-title":"Contrib Nephrol"},{"issue":"5","key":"5911_CR39","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1182\/blood-2009-01-199604","volume":"114","author":"T Hideshima","year":"2009","unstructured":"Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, Podar K, Mitsiades C, Munshi NC, Richardson PG, Carrasco RD, Anderson KC (2009) Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood 114(5):1046\u201352. https:\/\/doi.org\/10.1182\/blood-2009-01-199604","journal-title":"Blood"},{"issue":"10","key":"5911_CR40","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.3324\/haematol.11463","volume":"92","author":"H Ludwig","year":"2007","unstructured":"Ludwig H, Drach J, Graf H, Lang A, Meran JG (2007) Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. Haematologica 92(10):1411\u20131414. https:\/\/doi.org\/10.3324\/haematol.11463","journal-title":"Haematologica"},{"issue":"2","key":"5911_CR41","doi-asserted-by":"publisher","first-page":"330","DOI":"10.3109\/10428194.2011.619610","volume":"53","author":"J Minarik","year":"2012","unstructured":"Minarik J, Scudla V, Tichy T, Pika T, Bacovsky J, Lochman P, Zadrazil J (2012) Induction treatment of light chain deposition disease with bortezomib: rapid hematological response with persistence of renal involvement. Leuk Lymphoma 53(2):330\u2013331. https:\/\/doi.org\/10.3109\/10428194.2011.619610","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"5911_CR42","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s12185-011-0829-4","volume":"93","author":"H Fujita","year":"2011","unstructured":"Fujita H, Hishizawa M, Sakamoto S, Kondo T, Kadowaki N, Ishikawa T, Itoh J, Fukatsu A, Uchiyama T, Takaori-Kondo A (2011) Durable hematological response and improvement of nephrotic syndrome on thalidomide therapy in a patient with refractory light chain deposition disease. Int J Hematol 93(5):673\u2013676. https:\/\/doi.org\/10.1007\/s12185-011-0829-4","journal-title":"Int J Hematol"},{"issue":"24","key":"5911_CR43","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.2169\/internalmedicine.1018-18","volume":"57","author":"S Kimura","year":"2018","unstructured":"Kimura S, Ohkawara H, Ogawa K, Tanaka M, Sano T, Harada-Shirado K, Takahashi H, Ueda K, Shichishima-Nakamura A, Matsumoto H, Ikeda K, Kazama JJ, Hashimoto Y, Ikezoe T (2018) Lenalidomide as a Beneficial Treatment Option for Renal Impairment Caused by Light Chain Deposition Disease. Intern Med 57(24):3651\u20133657. https:\/\/doi.org\/10.2169\/internalmedicine.1018-18","journal-title":"Intern Med"},{"issue":"6","key":"5911_CR44","doi-asserted-by":"publisher","first-page":"461","DOI":"10.5414\/CN109342","volume":"89","author":"A Mima","year":"2018","unstructured":"Mima A, Nagahara D, Tansho K (2018) Successful treatment of nephrotic syndrome induced by lambda light chain deposition disease using lenalidomide: A case report and review of the literature. Clin Nephrol 89(6):461\u2013468. https:\/\/doi.org\/10.5414\/CN109342","journal-title":"Clin Nephrol"},{"issue":"Suppl 1","key":"5911_CR45","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1159\/000529776","volume":"147","author":"A Kobayashi","year":"2023","unstructured":"Kobayashi A, Takeda A, Shinjo H, Iguchi D, Ito C, Okada E, Goto N, Futamura K, Okada M, Hiramitsu T, Narumi S, Watarai Y (2023) Light Chain Deposition Disease Recurrence in Renal Allograft after Long-Term Remission. Nephron 147(Suppl 1):96\u2013100. https:\/\/doi.org\/10.1159\/000529776","journal-title":"Nephron"},{"issue":"1","key":"5911_CR46","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1053\/j.ajkd.2003.09.020","volume":"43","author":"N Leung","year":"2004","unstructured":"Leung N, Lager DJ, Gertz MA, Wilson K, Kanakiriya S, Fervenza FC (2004) Long-term outcome of renal transplantation in light-chain deposition disease. Am J Kidney Dis 43(1):147\u2013153. https:\/\/doi.org\/10.1053\/j.ajkd.2003.09.020","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"5911_CR47","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1159\/000046254","volume":"21","author":"AK Short","year":"2001","unstructured":"Short AK, O\u2019Donoghue DJ, Riad HN, Short CD, Roberts IS (2001) Recurrence of light chain nephropathy in a renal allograft. A case report and review of the literature. Am J Nephrol 21(3):237\u201340. https:\/\/doi.org\/10.1159\/000046254","journal-title":"Am J Nephrol"},{"issue":"10","key":"5911_CR48","doi-asserted-by":"publisher","first-page":"4407","DOI":"10.1016\/j.transproceed.2009.10.005","volume":"41","author":"Z Kaposztas","year":"2009","unstructured":"Kaposztas Z, Kahan BD, Katz SM, Van Buren CT, Cherem L (2009) Bortezomib successfully reverses early recurrence of light-chain deposition disease in a renal allograft: a case report. Transplant Proc 41(10):4407\u20134410. https:\/\/doi.org\/10.1016\/j.transproceed.2009.10.005","journal-title":"Transplant Proc"},{"issue":"10","key":"5911_CR49","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.2169\/internalmedicine.55.5752","volume":"55","author":"H Hiyamuta","year":"2016","unstructured":"Hiyamuta H, Yamada S, Matsukuma Y, Tsuchimoto A, Nakano T, Taniguchi M, Masutani K, Yoshimoto G, Muta T, Akashi K, Kitazono T, Tsuruya K (2016) Light Chain Deposition Disease in an Older Adult Patient Successfully Treated with Long-term Administration of Bortezomib. Melphalan and Prednisone Intern Med 55(10):1319\u20131325. https:\/\/doi.org\/10.2169\/internalmedicine.55.5752","journal-title":"Melphalan and Prednisone Intern Med"},{"issue":"1","key":"5911_CR50","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/s0272-6386(12)80314-3","volume":"20","author":"RL Heilman","year":"1992","unstructured":"Heilman RL, Velosa JA, Holley KE, Offord KP, Kyle RA (1992) Long-term follow-up and response to chemotherapy in patients with light-chain deposition disease. Am J Kidney Dis 20(1):34\u201341. https:\/\/doi.org\/10.1016\/s0272-6386(12)80314-3","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"5911_CR51","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/13506129.2021.1971192","volume":"28","author":"E Kastritis","year":"2021","unstructured":"Kastritis E, Rousakis P, Kostopoulos IV, Gavriatopoulou M, Theodorakakou F, Fotiou D, Dialoupi I, Migkou M, Roussou M, Kanellias N, Tselegkidi MI, Eleutherakis-Papaiakovou E, Papanikolaou A, Gakiopoulou C, Psimenou E, Spyropoulou-Vlachou M, Gatou A, Terpos E, Tsitsilonis O, Dimopoulos MA (2021) Consolidation with a short course of daratumumab in patients with AL amyloidosis or light chain deposition disease. Amyloid 28(4):259\u2013266. https:\/\/doi.org\/10.1080\/13506129.2021.1971192","journal-title":"Amyloid"},{"issue":"2","key":"5911_CR52","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/j.1523-1755.2004.00427.x","volume":"65","author":"B Royer","year":"2004","unstructured":"Royer B, Arnulf B, Martinez F, Roy L, Flageul B, Etienne I, Ronco P, Brouet JC, Fermand JP (2004) High dose chemotherapy in light chain or light and heavy chain deposition disease. Kidney Int 65(2):642\u2013648. https:\/\/doi.org\/10.1111\/j.1523-1755.2004.00427.x","journal-title":"Kidney Int"},{"issue":"7","key":"5911_CR53","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1182\/bloodadvances.2020001553","volume":"4","author":"P Milani","year":"2020","unstructured":"Milani P, Basset M, Curci P, Foli A, Rizzi R, Nuvolone M, Guido R, Gesualdo L, Specchia G, Merlini G, Palladini G (2020) Daratumumab in light chain deposition disease: rapid and profound hematologic response preserves kidney function. Blood Adv 4(7):1321\u20131324. https:\/\/doi.org\/10.1182\/bloodadvances.2020001553","journal-title":"Blood Adv"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05911-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05911-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05911-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T23:13:51Z","timestamp":1746400431000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05911-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,28]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["5911"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05911-9","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,28]]},"assertion":[{"value":"15 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}